WCG
TEVA icon

Weaver Consulting Group’s Teva Pharmaceuticals TEVA Stock Holding History

Weaver Consulting Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-395
Closed -$4K – 819
2020
Q3 		$4K Hold
395
– – ﹤0.01% 747
2020
Q2 		$5K Hold
395
– – ﹤0.01% 671
2020
Q1 		$4K Hold
395
– – ﹤0.01% 619
2019
Q4 		$3K Hold
395
– – ﹤0.01% 706
2019
Q3 		$3K Hold
395
– – ﹤0.01% 688
2019
Q2 		$4K Hold
395
– – ﹤0.01% 634
2019
Q1 		$4K Buy
+395
New +$6.97K ﹤0.01% 1173

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Weaver Consulting Group's TEVA Position: Q4 2020 in Review

Weaver Consulting Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2020, closing a stake of 395 shares — an estimated $4K sold.

Weaver Consulting Group first reported a position in TEVA in Q1 2019 and held it in 7 quarters. The position peaked at $5K in Q2 2020. 449 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

  • Weaver Consulting Group reported no remaining Teva Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 395 Teva Pharmaceuticals shares in Q4 2020, an estimated $4K.
  • Weaver Consulting Group first reported a position in Teva Pharmaceuticals in Q1 2019 and held it in 7 quarters.
  • Weaver Consulting Group's Teva Pharmaceuticals position peaked at $5K in Q2 2020.
  • 449 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.